HighTide Therapeutics (02511) Announces January 2026 Monthly Return
Bulletin Express
Feb 02
HighTide Therapeutics (02511) has disclosed its Monthly Return for the period ended 31 January 2026, confirming no changes in authorized share capital, which remains 1,000,000,000 ordinary shares at a par value of US$0.0001 for a total of US$100,000. The number of issued shares also remained constant at 571,325,668, with no treasury shares recorded.
The filing confirms compliance with the applicable public float requirement at the prescribed 25% threshold. No new share options, warrants, or convertible instruments were issued during the reporting period, and no other movements in issued shares were noted.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.